

Research and development in Czech Republic

Our mission is to discover new treatments to improve and extend people's lives. We use our own research and development to create innovative treatments across a range of therapeutic segments. Our research is focused mainly on areas where optimal treatments are not available. Thus we aim to address the needs of communities and patients around the world.



More than 5,600 of our employees globally are engaged in the research and development of new medicines in the Novartis Institutes for BioMedical Research (NIBR) - our specialized research division with campuses in 6 different locations across the globe. NIBR is the innovation engine of Novartis. Its staff collaborates across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

Main research areas:

- Immuno-oncology,
- Oncology,
- Neurology,
- Cardiovascular, renal and metabolic diseases,
- Autoimmunity, transplantation & inflammatory diseases,
- Ophthalmology,
- Neuromuscular diseases,
- Respiratory diseases,
- Tropical diseases.

Novartis is one of the leading pharmaceutical companies and invests heavily in research and development. Our investments in the Czech Republic amount to hundreds of millions of CZK annually.

List of links present in page

1. <https://prod1.novartis.cz/cz-cs/cz-cs/en/research-and-development/research-and-development-czech-republic>